The team behind Exscientia’s $60M Allcyte acquisition just raised $5M from Daphni to build their own drugs (opens in new tab)

The team behind Allcyte, acquired by Exscientia in a $60M deal, has raised $5M from Daphni to build its own drugs. The startup Graph is now moving from platform science to drug creation.